AMD

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

Long-term benefits and vision preservation using an extended macular vision IOL

Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

Investigators sought to understand the diagnostic path, symptoms, quality of life impact and coping mechanisms of patients with GA in western Europe and the United States

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

The study demonstrated that the number of injections needed gradually decreased during the follow-up period

Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.

Panelists discuss how the aflibercept 8 mg higher molecular concentration enables extended durability through increased VEGF binding capacity and longer intraocular drug levels, potentially allowing for less frequent dosing while maintaining efficacy.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully determined based on disease activity markers.